StemCell Therapy

New York, March 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cloud Computing in Cell Biology, Genomics and Drug Development" - https://www.reportlinker.com/p05873501/?utm_source=GNW The report analyzes trends and dynamics including drivers, limitations, challenges and opportunities.

The report discusses strategies adopted by emerging market players with recommendations for new market entrants.This research study discusses historical, current and potential market size.

The report will help market players and new entrants to make informed decisions about the production and export of goods and services, as well as providing organizations, distributors and exporters information about market development and trends.The study segments the market on the basis of applications and end uses.

A geographical market analysis is provided for all major segments.

Report Includes: - 43 data tables and 18 additional tables - An overview of the global market for cloud computing applications in cell biology, genomics and drug development - Analyses of global and regional market trends, with data from 2018 to 2019, and projections of compound annual growth rates (CAGRs) through 2024 - Assessment of market trends and opportunities, key developments and the impact of cloud computing technology on the biotechnology, pharmaceutical and healthcare industry verticals - Insight into recent developments in cloud infrastructure and information pertaining to key partnerships between cloud service providers and pharma/biotech companies and investment in pharmaceutical R&D sector - Discussion of the suppliers' landscape, as well as the market positioning and strategies of key manufacturers and suppliers for cloud computing applications - Review of patent applications filed regarding cloud computing technology in the U.S. healthcare sector - Company profiles of the leading market players, including Amazon Web Services (AWS) Inc., Cisco Systems Inc., DXC Technology, Google LLC, Salesforce.com Inc., and SAP SE

Summary The global market for cloud computing in cell biology, genomics and drug development is estimated to grow at a CAGR of REDACTED during the forecast period.The market was valued at REDACTED in 2018 and is expected to reach REDACTED in 2024.

In biomedical research, cloud computing has resolved big data concerns and improves data, analytics, collaboration and sharing. Increasing biomedical research based on human, animal, plants, and microbes has increased the dependency on proper storage and network infrastructure as well as secure and scalable computing.

With growing big data concerns, researchers are inclined towards cloud computing platforms.These platforms provide flexibility to users to pay according to their usage of cloud services including software, hardware infrastructure and platforms to solve biomedical computation concerns.

The cloud offers ondemand storage and an analysis facility to users which makes it an emerging computing platform to address big data concerns.Owing to the flexibility and cost-effectiveness, cloud services are gaining significant importance in life science research for data storage, communication and collaboration with stakeholders.

On cloud platforms, large datasets and applications for gene sequencing, image analysis, protein folding and data mining can be shared for collaborative research between facilities.

The major pivotal factors contributing to the growth of the market include rising genomics and proteomics research and the increasing number of clinical trials performed across various countries.Considerable public and private investment in genomics and proteomics research is providing support to biotechnology start-ups and research institutes.

This helps healthcare providers to develop and commercialize genomics technologies and personalized medicines. Increasing U.S. FDA approvals for personalized medicines are supporting the growth in genomics research. For example, according to the Personalized Medicine Coalition, in 2018, approximately REDACTED of the REDACTED new molecular entities (NMEs) approved by the FDA are personalized medicines which constitute REDACTED of all new drug approvals. The Coalition classified REDACTED of NMEs as personalized medicines in 2017, REDACTED in 2015 and REDACTED in 2016. The U.S. FDA is making efforts to facilitate access to genomic testing and integration of real-world evidence into its regulatory framework. As a result, the FDA has begun to authorize the marketing of cancer-related genetic tests, and pharmacogenetics were allowed to be sold directly to the consumers. This has resulted in the development of personalized medicine as an emerging practice of medicine that utilizes the genetic profile of an individual to make appropriate decisions regarding prevention, diagnosis and treatment of the condition. Gaining complete knowledge about the patient's genetic profile helps doctors to choose proper therapy or medication and to administer it with the proper regimen or dose. Significant data is generated by sequencing a single human genome which necessitates the adoption of cloud services. The 1000 Genomes Project is an effort to sequence genomes of at least a thousand people from across the globe to develop the most comprehensive and medically relevant picture of human genetic variation. This initiative intends to make genomic data easily accessible from international research institutions. Major support for the project is offered by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), Wellcome Trust Sanger Institute in Hinxton, England and the Beijing Genomics Institute, Shenzhen (BGI Shenzhen) in China.Read the full report: https://www.reportlinker.com/p05873501/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Excerpt from:
Cloud Computing in Cell Biology, Genomics and Drug Development - Benzinga

This entry was posted on March 9, 2020 at 7:46 pm and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |